[Clinical evaluation of 18-fluorine fluorodeoxyglucose positron emission tomography-CT imaging in head and neck tumors].
To study the clinical value of 18-fluorine fluorodeoxyglucose (18 F-FDG) positron emission tomography (PET)-CT imaging in diagnosis and detection of primary tumors and suspicious recurrence in head and neck cancers. Twenty-seven patients with primary tumors or metastases in head and neck underwent 18F-FDG PET-CT imaging, and compared with clinical data. 1. In 4 NPC diagnosed pre-radiation patients the 18F-FDG PET-CT imaging in nasopharynx was all positive, 2 of them were detected with neck lymph node metastases, which were confirmed later histopathologically. In 12 NPC cases after radiation, 4 were not found any evidence of tumor with PET-CT imaging and clinically, 4 were detected neck recurrence and confirmed histopathologically, 2 had remote metastases confirmed by other imaging, 2 were detected and confirmed recurrence in primary sites and one of them in regional and remote site. 2. In 4 neck metastatic patients with unknown primary tumor, the primary tumors were all identified, 3 of them were confirmed histopathologically. 3. Seven patients with other head and neck tumors after therapy underwent 18F-FDG PET-CT imaging. Two patients had no evidence of recurrence. Five patients were detected recurrence or metastases, 4 of them were confirmed histopathologically, one of them refused biopsy. With metabolic image of PET and anatomic image of CT, 18F-FDG PET-CT is a kind of very useful way in diagnosing primary tumor and detecting the recurrence and metastases in patients with head and neck tumor.